Education
About Us
Working with TipRanks
Follow Us
Starpharma Holdings Limited (AU:SPL)
ASX:SPL
RESEARCH TOOLSreports
SPL Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.13
Previous CloseN/A
Volume337.59K
Average Volume (3M)399.29K
Market Cap
$41.82M
Enterprise ValueAU$24.02M
Total Cash (Recent Filing)$20.28M
Total Debt (Recent Filing)AU$2.48M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
Aug 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding418,224,800
10 Day Avg. Volume165,416
30 Day Avg. Volume399,290
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-3.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Starpharma Holdings Limited News
PremiumCompany Announcements
Starpharma Announces Cessation of Performance Rights
PremiumCompany Announcements
Change in Substantial Holder’s Voting Power at Starpharma Holdings
PremiumCompany Announcements
Robmar Investments Alters Stake in Starpharma Holdings
PremiumCompany Announcements
Starpharma Advances Strategic Initiatives and Expands Market Presence
PremiumCompany Announcements
Starpharma Announces Quotation of New Securities on ASX
PremiumCompany Announcements
Robmar Investments Acquires Substantial Stake in Starpharma Holdings
PremiumCompany Announcements
Starpharma Reports Revenue Growth and Regulatory Milestone for DEP® SN38PremiumCompany Announcements
Starpharma Highlights DEP® Dendrimer Platform at PepTalk ConferenceOptions Prices
Currently, No data available
---
Ownership Overview
1.26% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
98.74% Public Companies and
Individual Investors
SPL FAQ
What was Starpharma Holdings Limited’s price range in the past 12 months?
Starpharma Holdings Limited lowest share price was AU$0.08 and its highest was AU$0.13 in the past 12 months.
What is Starpharma Holdings Limited’s market cap?
Starpharma Holdings Limited’s market cap is $41.82M.
When is Starpharma Holdings Limited’s upcoming earnings report date?
Starpharma Holdings Limited’s upcoming earnings report date is Aug 20, 2025 which is in 32 days.
How were Starpharma Holdings Limited’s earnings last quarter?
Currently, no data Available
Is Starpharma Holdings Limited overvalued?
According to Wall Street analysts Starpharma Holdings Limited’s price is currently Overvalued.
Does Starpharma Holdings Limited pay dividends?
Starpharma Holdings Limited does not currently pay dividends.
What is Starpharma Holdings Limited’s EPS estimate?
Starpharma Holdings Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Starpharma Holdings Limited have?
Starpharma Holdings Limited has 418,224,800 shares outstanding.
What happened to Starpharma Holdings Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Starpharma Holdings Limited?
Currently, no hedge funds are holding shares in AU:SPL
Starpharma Holdings Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:SPL Sentiment 61%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.63%
12-Months-Change
Fundamentals
Return on Equity
-43.63%
Trailing 12-Months
Asset Growth
-38.83%
Trailing 12-Months
Company Description
Starpharma Holdings Limited
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Prescient Therapeutics Limited
―
Island Pharmaceuticals Ltd
―
Noxopharm Ltd.
―
Avecho Biotechnology Limited
―